APA (7th ed.) Citation

Lorenzen, S., Haag, G. M., Eisenmenger, A., Karapanagiotou-Schenkel, I., & Lordick, F. (2015). Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. European journal of cancer, 51(5), . https://doi.org/10.1016/j.ejca.2015.01.059

Chicago Style (17th ed.) Citation

Lorenzen, Sylvie, Georg Martin Haag, Andreas Eisenmenger, Irini Karapanagiotou-Schenkel, and Florian Lordick. "Lapatinib Versus Lapatinib Plus Capecitabine as Second-line Treatment in Human Epidermal Growth Factor Receptor 2-amplified Metastatic Gastro-oesophageal Cancer: A Randomised Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie." European Journal of Cancer 51, no. 5 (2015). https://doi.org/10.1016/j.ejca.2015.01.059.

MLA (9th ed.) Citation

Lorenzen, Sylvie, et al. "Lapatinib Versus Lapatinib Plus Capecitabine as Second-line Treatment in Human Epidermal Growth Factor Receptor 2-amplified Metastatic Gastro-oesophageal Cancer: A Randomised Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie." European Journal of Cancer, vol. 51, no. 5, 2015, https://doi.org/10.1016/j.ejca.2015.01.059.